Back to the drawing board on immunohistochemistry and predictive factors

Journal of the National Cancer Institute

Volumn 97, Issue 24, 2005, Pages 1796-1797

  Henson, Donald Earl ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TAMOXIFEN;

CANCER; CANCER CELL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EDITORIAL; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STANDARDIZATION; TISSUE MICROARRAY;

ANTIBODIES, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 29844433090     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji449     Document Type: Editorial

References (23)

1. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-15.
2. McCluggage WG, Connolly LE, McGregor G, Hyland PL, Hall PA. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynecol Pathol 2005;24:307-12.
3. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 1998;52:79-98.
4. Mirlacher M, Kasper M, Storz M, Knecht Y, Durmuller U, Simon R, et al. Influence of slide aging on results of translational research studies using immunochemistry. Mod Pathol 2004;17:1414-20.
5. McCormick D, Yu C, Hobbs C, Hall PA. The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology 1993;22:543-7.
6. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63: 1445-8.
7. Ambros RA, Sheehan CE, Kallakury BV, Ross JS, Malfetano J, Paunovich E, et al. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. Mod Pathol 1996;9:1165-9.
8. Stewart RL, Royds JA, Burton JL, Heatley MK, Wells M. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology 33:1998: 440-5.
9. Pallares J, Bussaglia E, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, et al. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005;18:719-27.
10. Lambkin HA, Mothersill CM, Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 1994;172:13-8.
11. Rudiger T, Hofler H, Kreipe HH, Nizze H, Pfeifer U, Stein H, et al. Quality assurance in immunochemistry: Results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873-82.
12. Taylor CR. The total test approach to standardization of immunochemistry. Arch Pathol Lab Med 2000;124:945-51.
13. Taylor CR. Report from the Biological Stain Commission: FDA issues final rule for classification/reclassification of immunohistochemistry reagents and kits. Biotech Histochem 1998;73:175-7.
14. Taylor CR. An exaltation of experts: Concerted efforts in the standardization of immunochemistry. Hum Pathol 1994;25:2-11.
15. DeLellis RA, Sternberger LA, Mann RB, Banks PM, Nakane PK. Immunoperoxidase techniques in diagnostic pathology. Report of a workshop sponsored by the National Cancer Institute. Am J Clin Pathol 1979;71:483-8.
16. O'Leary T. Standardization in immunochemistry. Appl Immunohistochem 2001;9:3-8.
17. Mengel M, Hebel K, Kreipe H, von Wasielewski R. Standardized on-slide control for quality assurance in the immunohistochemical assessment of therapeutic target molecules in breast cancer. Breast J 2005;11:34-40.
18. Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88:1054-9.
19. Bertheau P, Cazals-Hatem D, Meignin V, de Roquancourt A, Verola O, Lesourd A, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998;51:370-4.
20. Shi SR, Cote RJ, Taylor CR. Antigen retrieval techniques: Current perspectives. J Histochem Cytochem 2001;49:931-8.
21. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results of laboratories in 21 countries. Am J Clin Pathol 2002; 118:408-17.
22. Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohistochemical demonstration of estrogen and progesterone receptors: Correlation of standards achieved on in house tumors with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000;53:292-301.
23. Muro-Cacho CA. The role of immunochemistry in the differential diagnosis of soft-tissue tumors, http://www.moffitt.usf.edu/pubs/ccj/v5n1/ department5.html.